The Center for Outcomes Research and Economic Evaluation for Health (CORE2-Health; C2H) of the National Institute of Public Health has selected St. Luke’s International University as an analysis agency to evaluate medicines and medical devices for the cost-effectiveness evaluation system. This initiative was introduced for the first time in Japan in April 2019. St. Luke’s International University is one of the two selected institutions, along with Ritsumeikan University.

In this cost-effectiveness evaluation system, in relation to drug price calculation, a manufacturer (such as a pharmaceutical company) first submits cost-effectiveness data for their products. Subsequently, the Center for Outcomes Research and Economic Evaluation for Health (CORE2-Health; C2H) of the National Institute of Public Health, together with St. Luke’s International University, will conduct a review and cost-effectiveness evaluation as a neutral entity, and submit a report to the government.

St. Luke's International University, as the first cost-effectiveness analysis implementation agency, brings together excellent researchers to establish a neutral and transparent re-analysis organization, and will continue to contribute to this new and innovative system. Moreover, we will work as a central organization in this field in Japan and play a leading role in medical economics research and human resource development in this field.